Case Report

Case of Eosinophilic Cystitis Treated with Suplatast Tosilate as Maintenance Therapy

Tateki Yoshino and Hiroyuki Moriyama

Department of Urology, JA Onomichi General Hospital, Hiroshima 722-0018, Japan

Correspondence should be addressed to Tateki Yoshino, uroltatke@yahoo.co.jp

Received 18 June 2012; Accepted 15 August 2012

Academic Editors: S. K. Hong and E. Tuzel

Copyright © 2012 T. Yoshino and H. Moriyama. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Eosinophilic cystitis is a rare inflammatory lesion of the bladder, characterized by massive eosinophilic infiltration of the bladder wall. Its cause is not known definitely. A 49-year-old man consulted our department with a miction pain, gross hematuria, and frequent micturition. Urinalysis showed combined hematuria and pyuria, but urine culture was sterile. Abnormal findings of laboratory examination included an elevated white blood cell (WBC) count (15,700/µL) and the proportion of eosinophils in the peripheral blood was 12% of the WBCs (normal 0–5%). Cystoscopy revealed a solid mass with severe edematous mucosa. Magnetic resonance imaging (MRI) also indicated marked bladder wall thickening, which was suspected for invasive bladder cancer. Transurethral biopsy of the bladder mass was performed with pathological examination revealing features of eosinophilic cystitis. After administration of a combination of prednisolone and suplatast tosilate, followed by monotherapy with suplatast tosilate, regression of the bladder mass, and normalization of the count of peripheral eosinophils were achieved. Fourteen months after steroid therapy, under treatment with suplatast tosilate, there was no relapse of urinary symptoms and the bladder mass.

1. Introduction

Eosinophilic cystitis is a rare inflammatory lesion of the bladder of unknown origin. The majority of knowledge about this disorder is based on the case reports. Brown [1] and Palubinskas [2] first reported the disease in 1960. Not frequently, the disease mimic the bladder cancer with clinical, radiographic, and cystoscopic features. The definitive diagnosis can be made only by histopathological examination of biopsy specimens. In this report, we present a case of eosinophilic cystitis mimicking invasive bladder cancer treated with prednisolone and suplatast tosilate.

To our knowledge, this is the first case of eosinophilic cystitis treated with suplatast tosilate in the English literature.

2. Case Report

A 49-year-old man consulted our department with a miction pain, gross hematuria, and frequent micturition. His past medical history included none. He had experienced no signs of rheumatoid disease, bronchial asthma, or other known allergic disease and had received no medication. There was no history of urinary symptoms and urinary tract infection. The results of physical examination were unremarkable.

Urinalysis showed combined hematuria and pyuria, but urine culture was sterile. Urine cytology indicated atypical cells. Abnormal findings of laboratory examination included an elevated WBC count (15,700/µL) and the proportion of eosinophils in the peripheral blood was 12% of the WBCs (normal 0–5%). Immunoglobulin analysis showed normal range of IgE (9.8 IU/mL, normal < 173 IU/mL). In spite of administration of antibiotics, his symptoms and urinalysis result did not improved.

Cystoscopy revealed a solid mass covered with clots at the dome to anterior wall and several diverticula of the bladder with severe edematous mucosa. Contrast-enhanced MRI also indicated marked bladder wall thickening exceeding 15 mm (Figure 1(a)), which was suspected for invasive bladder cancer.

Transurethral biopsy of the bladder mass was performed with pathological examination revealing features of eosinophilic cystitis, infiltration of abundant eosinophils
(a) MRI before treatment showed marked bladder wall thickening exceeding 15 mm mimicking invasive bladder cancer

(b) MRI after the initiation of treatment showed regression of the bladder mass

**Figure 1:** MRI findings (sagittal section). Arrow; bladder wall thickening.

The patient was given a combination of prednisolone 30 mg per day with a tapering course for 8 weeks and suplatast tosilate, followed by monotherapy with suplatast tosilate. After treatment, regression of the bladder mass (Figure 1(b)), and normalization of the count of peripheral eosinophils (2.7% of the WBCs) were achieved. In addition, cystoscopic findings two months after the initiation of treatment indicated the improvement of bladder mass and edematous mucosa. Fourteen months after steroid therapy, under treatment with suplatast tosilate, there was no relapse of urinary symptoms and the bladder mass.

From the submucosa to the muscular layer being evident (Figure 2).

**Figure 2:** Microscopic appearance of the bladder wall with massive infiltration of eosinophils into the muscular layer.

The etiology of eosinophilic cystitis remains unknown, but it is believed to be associated with injury; drugs (e.g., methicillin, warfarin, anthranilic acid, intravesical mitomycin, and thiopeta); bacterial, viral, and parasitic infections; and reactions to food (e.g., vegetables, spices, and chocolate), and other allergens. Allergic reactions have been suggested to be predisposing factors in the pathogenesis and food allergy, and hypersensitivity to inhalant allergens and drugs have been discussed in relation to urinary tract lesions. It has been reported that peripheral eosinophilia is present in 43% of patients with eosinophilic cystitis, but elevated serum IgE is uncommon [4], and their interrelations are unclear. In the past report [5], urinalyses of 77% of patients showed hematuria and/or pyuria. The ratio of positive urine culture was only 20.5%.

Radiographic findings may show variable thickening of the bladder wall, ranging from diffuse thickening to mass formation. The pseudotumorous form of eosinophilic cystitis is characterized by an extensive infiltration of the bladder wall that may resemble an invasive tumor [6].

Diagnosis can be made by histological examination of a biopsy specimen of the bladder. Histologically, the submucosa is edematous, containing a mixed inflammatory infiltrate in which eosinophils are prominent. Eosinophilic infiltration may be the final pathway by which endogenous and exogenous allergens cause IgE-mediated degranulation of mast cells and the release of eosinophilic chemotactic factors, such as various cytokines. Additionally, previous studies suggested that activated eosinophils released cytoxic cationic proteins that could induce tissue damage [7]. These mechanisms were speculated for primary disease process of eosinophilic cystitis [8].

While treatment for eosinophilic cystitis has not yet been standardized, it was reported as follows: (1) removal of the allergen or discontinuation of drug when an allergy is the clear cause; (2) administration of an antihistaminic agent and NSAIDs; (3) administration of steroids; (4) transurethral
resection of the disorder lesion; or (5) administration of immunosuppressive agents, such as cyclosporine. Because of probable immunologic nature of disease, corticosteroids have become the mainstay of the treatment, especially in patients who have an unresolved disease with anti-inflammatory drugs and antihistamines and have wide tumoral lesions.

In the present case, because oral suplatast tosilate was effective for eosinophilic cystitis, prednisolone was tapered gradually and withdrawn. To our knowledge, this is the first case of eosinophilic cystitis treated with suplatast tosilate in the English literature. Previous Japanese literature have also reported the efficacy of suplatast tosilate for eosinophilic cystitis [9]. Suplatast tosilate was widely known as a therapeutic agent for bronchial asthma, atopic dermatitis, and allergic rhinitis. In action mechanisms of suplatast tosilate, it inhibits the production of helper T-cell-derived interleukin 4 and 5 (IL-4 and IL-5), suppressing the production of IgE from B cells and cytokines from mast cells [10]. In addition, low production of IL-5 leads to the inhibition of eosinophil differentiation and activation, and further, the release of cytotoxic cationic proteins which can induce tissue damage [11]. Thinking of primary disease process of eosinophilic cystitis, it was regarded that suplatast tosilate is efficacious for this disorder from its action mechanisms.

Only in patients who have a disease intractable to conservative treatments as previously mentioned and presenting as profuse hematuria, contracted bladder, uni- or bilateral distal ureteral involvement together with renal failure, partial or total cystectomy, and diversion must be considered [3, 4, 12].

References

[1] E. W. Brown, “Eosinophilic granuloma of the bladder,” The Journal of Urology, vol. 83, pp. 665–668, 1960.

[2] A. J. Palubinskas, “Eosinophilic cystitis. Case report of eosinophilic infiltration of the urinary bladder,” Radiology, vol. 75, pp. 589–591, 1960.

[3] N. M. B. Itano and R. S. Malek, “Eosinophilic cystitis in adults,” Journal of Urology, vol. 165, no. 3, pp. 805–807, 2001.

[4] D. Van Den Ouden, “Diagnosis and management of eosinophilic cystitis. A pooled analysis of 135 cases,” European Urology, vol. 37, no. 4, pp. 386–394, 2000.

[5] S. Kiliç, R. Erguvan, D. Ipek et al., “Eosinophilic cystitis: a rare inflammatory pathology mimicking bladder neoplasms,” Urologia Internationalis, vol. 71, no. 3, pp. 285–289, 2003.

[6] K. A. Barry and S. Z. H. Jafri, “Eosinophilic cystitis: CT findings,” Abdominal Imaging, vol. 19, no. 3, pp. 272–273, 1994.

[7] P. F. Weller, “The immunobiology of eosinophils,” New England Journal of Medicine, vol. 324, no. 16, pp. 1110–1118, 1991.

[8] S. Dubucquoi, A. Janin, P. Desreumaux et al., “Evidence for eosinophil activation in eosinophilic cystitis,” European Urology, vol. 25, no. 3, pp. 254–258, 1994.

[9] M. Watanabe, K. Yamaguchi, T. Yamanishi, T. Kamai, and K. Yoshida, “A case of eosinophilic cystitis that was treated with oral suplatast tosilate (IPD-1151T),” Acta Urologica Japonica, vol. 55, no. 11, pp. 715–719, 2009.

[10] Y. Yanagihara, M. Kiniwa, K. Ikizawa, T. Shida, N. Matsuura, and A. Koda, “Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2) regulation of human IgE response,” Japanese Journal of Pharmacology, vol. 61, no. 1, pp. 31–39, 1993.

[11] H. Yamaya, Y. Basaki, M. Togawa, M. Kojima, M. Kiniwa, and N. Matsuura, “Down-regulation of TH2 cell-mediated murine peritoneal eosinophilia by antiallergic agents,” Life Sciences, vol. 56, no. 19, pp. 1647–1654, 1995.

[12] H. Y. Lin, Y. H. Chou, W. J. Wu, C. H. Huang, and C. Y. Chai, “Eosinophilic cystitis: eight cases report and literature review,” The Kaohsiung Journal of Medical Sciences, vol. 18, no. 1, pp. 30–34, 2002.